	US 11,938,156 B2
	Lactic acid bacteria and its applications
Ying-Chieh Tsai, Taipei (TW); Hui-Yu Huang, Taipei (TW); Chien-Chen Wu, Taipei (TW); and Jyh-Shing Hsu, Taipei (TW)
Assigned to BENED BIOMEDICAL CO., LTD., Taipei (TW)
Appl. No. 16/959,891
Filed by BENED BIOMEDICAL CO., LTD., Taipei (TW)
PCT Filed Jan. 4, 2019, PCT No. PCT/CN2019/070494 § 371(c)(1), (2) Date Jul. 2, 2020, PCT Pub. No. WO2019/134690, PCT Pub. Date Jul. 11, 2019.
Claims priority of provisional application 62/614,296, filed on Jan. 5, 2018.
Prior Publication US 2021/0085731 A1, Mar. 25, 2021
Int. Cl. A61K 35/747 (2015.01); A61K 9/00 (2006.01); A61P 1/00 (2006.01); A61P 21/06 (2006.01); A61P 25/22 (2006.01); A61P 25/24 (2006.01); A61P 25/28 (2006.01); C12N 1/20 (2006.01); C12R 1/225 (2006.01)

CPC A61K 35/747 (2013.01) [A61K 9/0056 (2013.01); A61P 1/00 (2018.01); A61P 21/06 (2018.01); A61P 25/22 (2018.01); A61P 25/24 (2018.01); A61P 25/28 (2018.01); C12N 1/205 (2021.05); C12R 2001/225 (2021.05)]

5 Claims

1. A method for (i) treating or preventing inflammatory bowel syndrome a subject in need thereof, (ii) treating or preventing anxiety, inflammation, and/or HPA axis dysfunction in a subject suffering from maternal separation (MS) and/or (iii) treating or preventing sarcopenia in a subject in need thereof, comprising administering the isolated and purified lactic acid bacteria Lactobacillus paracasei PS23 (PS23), deposited with Deutsche Sammlung von Mikroorganismen und Zellkulturen under Budapest Treaty and was given the accession number DSM 32322 or a composition comprising PS23 to the subject, wherein the PS23 is administered in an amount ranging from about 1×10⁷to about 1×10¹³cells/day of heat-killed PS23 cells or about 1×10⁷to about 1×10¹³CFU/day of live PS23 cells.